Connor, Clark & Lunn Investment Management (CC&L)’s Precision BioSciences DTIL Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio DTIL Stock Details DTIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,852	Closed	-$102K	–	1300
2022 Q4	$102K	Sell	2,852 -1,041	-27%	-$41.1K	﹤0.01%	1108
2022 Q3	$152K	Buy	3,893 +488	+14%	+$23.2K	﹤0.01%	1019
2022 Q2	$163K	Buy	3,405 +3,017	+778%	+$177K	﹤0.01%	955
2022 Q1	$36K	Buy	388 +13	+3%	+$1.77K	﹤0.01%	1007
2021 Q4	$83K	Sell	375 -8	-2%	-$2.23K	﹤0.01%	1037
2021 Q3	$133K	Buy	+383	New	+$130K	﹤0.01%	968

Other funds holding DTIL

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s DTIL Position: Q1 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Precision BioSciences (DTIL) in Q1 2023, closing a stake of 2,852 shares — an estimated $102K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in DTIL in Q3 2021 and held it in 6 quarters. The position peaked at $163K in Q2 2022. 86 funds tracked by Wall St. Rank hold DTIL as of Q1 2023.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Precision BioSciences position as of Q1 2023 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 2,852 Precision BioSciences shares in Q1 2023, an estimated $102K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Precision BioSciences in Q3 2021 and held it in 6 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Precision BioSciences position peaked at $163K in Q2 2022.
86 funds tracked by Wall St. Rank held Precision BioSciences as of Q1 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2023, filed 10 May 2023.